ISCT Clinical Translation Committee recommendations on mesenchymal stromal cells in GVHD: easy manufacturing is faced with standardizing and commercialization challenges

Abstract

Mesenchymal Stromal Cells (MSCs) have been used in multiple clinical trials for steroid-refractory moderate-severe (grade II-IV) acute Graft-versus-Host Disease (aGvHD) across the world over the last 2 decades. Despite very promising results in a variety of trials, it failed to get widespread approval by regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. What lessons can we learn from this for future studies on MSCs and other cell therapy products? Broad heterogeneity among published trials using MSCs in aGVHD was likely the core problem. We propose a standardized approach in regards to donor-related factors, MSCs-related characteristics, as well as clinical trial design, to limit heterogeneity in trials for aGVHD and to fulfill the requirements of regulatory agencies. This approach may be expanded beyond MSCs to other Cell and Gene therapy products and trials in other diseases.